文献速递艾滋病与性传播感染

多替拉韦与依非韦伦方案在妊娠期治疗对孕妇及其婴儿红细胞叶酸浓度的影响

Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.
PubMed 文献 · J Infect Dis · 2024-01-01

在IMPAACT 2010/VESTED研究中,孕妇随机接受多替拉韦(DTG)联合恩曲他滨(FTC)/替诺福韦艾拉酚胺(TAF)、DTG联合FTC/富马酸替诺福韦二吡呋酯(TDF)或依非韦伦(EFV)/FTC/TDF方案。研究评估了340名母亲和310名婴儿的红细胞叶酸浓度,发现各方案间所有红细胞叶酸结局均无临床意义上的差异。

要点

  • 孕妇入组时各方案组红细胞叶酸浓度相似。
  • DTG+FTC/TAF组母亲叶酸轨迹较EFV/FTC/TDF组高3%(调整几何均值比1.03,95%CI 1.00-1.06)。
  • DTG+FTC/TAF组婴儿与母亲叶酸比值较EFV/FTC/TDF组低8%(0.92,95%CI 0.78-1.09)。

核心结论

  • 结果一致,各方案间所有红细胞叶酸结局均无临床意义上的差异,提示开始以DTG为基础与以EFV为基础的抗逆转录病毒治疗的孕妇,其叶酸细胞摄取和向婴儿的转运无差异。

研究设计与样本

  • 研究为IMPAACT 2010/VESTED随机试验的一部分,孕妇随机接受DTG+FTC/TAF、DTG+FTC/TDF或EFV/FTC/TDF方案。
  • 评估了340名母亲和310名婴儿在母亲入组时、分娩时及婴儿出生时的红细胞叶酸浓度。

主要发现

  • 总体90%的母亲补充叶酸,78%居住在非洲。
  • 入组时母亲中位年龄25岁,中位孕周22周,中位CD4计数482细胞/μL,中位log10 HIV RNA 3拷贝/mL。
  • 入组时各方案组红细胞叶酸相似。
  • 母亲叶酸轨迹的调整几何均值比在DTG+FTC/TAF组较EFV/FTC/TDF组高3%(1.03,95%CI 1.00-1.06)。
  • 婴儿与母亲叶酸比值在DTG+FTC/TAF组较EFV/FTC/TDF组低8%(0.92,95%CI 0.78-1.09)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 2010/VESTED study, pregnant women were randomized to initiate dolutegravir (DTG) + emtricitabine (FTC)/tenofovir alafenamide (TAF), DTG + FTC/tenofovir disoproxil fumarate (TDF), or efavirenz (EFV)/FTC/TDF. METHODS: We assessed red blood cell (RBC) folate concentrations at maternal study entry and delivery, and infant birth. RBC folate outcomes were (1) maternal change entry to delivery (trajectory), (2) infant, and (3) ratio of infant-to-maternal delivery. Generalized estimating equation models for each log(folate) outcome were fit to estimate adjusted geometric mean ratio (Adj-GMR)/GMR trajectories (Adj-GMRTs) of each arm comparison in 340 mothers and 310 infants. RESULTS: Overall, 90% of mothers received folic acid supplements and 78% lived in Africa. At entry, median maternal age was 25 years, gestational age was 22 weeks, CD4 count was 482 cells/μL, and log10 HIV RNA was 3 copies/mL. Entry RBC folate was similar across arms. Adj-GMRT of maternal folate was 3% higher in the DTG + FTC/TAF versus EFV/FTC/TDF arm (1.03 [95% confidence interval {CI}, 1.00-1.06]). The DTG + FTC/TAF arm had an 8% lower infant-maternal folate ratio (0.92 [95% CI, .78-1.09]) versus EFV/FTC/TDF. CONCLUSIONS: Results are consistent, with no clinically meaningful differences between arms for all RBC folate outcomes, and they suggest that cellular uptake of folate and folate transport to the infant do not differ in pregnant women starting DTG- versus EFV-based antiretroviral therapy. CLINICAL TRIALS REGISTRATION: NCT03048422.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Jacobson DL, Crider KS, DeMarrais P, et al. Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants. J Infect Dis. 2024. PMID: 38877762. doi:10.1093/infdis/jiae308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。